- PharmaDrug (PHRX) engages Octagon Media and affiliated Wall Street Reporter for investor marketing campaign
- Octagon Media Corp. will receive a payment of US$60,000 as well as 3,400,000 common shares of PharmaDrug
- The shares will be subject to a statutory four month hold
- PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines
- PharmaDrug Inc. (PHRX) is up 20 per cent, trading at C$0.06 at 1:39 pm EST
PharmaDrug Inc. (PHRX) has engaged Octagon Media Corp to assist in a digital media advertising campaign coupled with an investor marketing program.
As compensation, Octagon Media Corp. will receive a payment of US$60,000 as well as 3,400,000 common shares of PharmaDrug.
The shares will be subject to a statutory four-month hold. It will also grant Octagon Media Corp incentive stock options to purchase up to 3 million common shares in the capital of the company at an exercise price of $0.05 CAD per share for a 12 month period.
Octagon Media Corp.’s services consist of the Wall Street Reporter and Next Super Stock platforms.
The services will include investor conferences, features on the WallStreetReporter.com website, CEO podcast interviews as well as social media and targeted email distribution. The term of the contract is for six months.
Daniel Cohen, Chairman and CEO of PharmaDrug, commented, “We believe the company is well-positioned to benefit from a wider U.S. investor audience due to its emerging biotech strategy and are confident The Wall Street Reporter can help us achieve that goal.”
Following posting its shares on the OTCQB in October of 2021, its common shares became DTC eligible last week, thereby increasing the accessibility of the common shares to U.S. investors.
PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs.
PharmaDrug owns 100 per cent of Pharmadrug Production GmbH, a German medical cannabis distributor, with a Schedule I European Union narcotics license and German EuGMP certification allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the European Union.
PharmaDrug Inc. (PHRX) is up 20 per cent, trading at C$0.06 at 1:39 pm EST.